相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
Andrew M. Blumenfeld et al.
JOURNAL OF HEADACHE AND PAIN (2018)
Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data
Brendan Davies et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Quarterly repeat cycles of onabotulinumtoxinA in chronic migraine patients: the benefits of the prolonged treatment on the continuous responders and quality-of-life conversion rate in a real-life setting
Antonio Santoro et al.
NEUROLOGICAL SCIENCES (2017)
Long-term Treatment Benifits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
Simona Guerzoni et al.
FRONTIERS IN NEUROLOGY (2017)
Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe
Manjit Matharu et al.
CEPHALALGIA (2017)
A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience
Andrea Negro et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study
David W. Dodick et al.
HEADACHE (2016)
Onabotulinumtoxin-A treatment in Greek patients with chronic migraine
Michail Vikelis et al.
JOURNAL OF HEADACHE AND PAIN (2016)
Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting
Katja Kollewe et al.
JOURNAL OF NEURAL TRANSMISSION (2016)
Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study
Dawn C. Buse et al.
MAYO CLINIC PROCEEDINGS (2016)
Unmet clinical needs in chronic migraine: Rationale for study and design of COMPEL, an open-label, multicenter study of the long-term efficacy, safety, and tolerability of onabotulinumtoxinA for headache prophylaxis in adults with chronic migraine
Andrew M. Blumenfeld et al.
BMC NEUROLOGY (2015)
Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine
Kasra Maasumi et al.
HEADACHE (2015)
Best Practices for Patients With Chronic Migraine: Burden, Diagnosis, and Management in Primary Care
Amaal J. Starling et al.
MAYO CLINIC PROCEEDINGS (2015)
OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study
Andrea Negro et al.
SPRINGERPLUS (2015)
OnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigm
Maria Isabel Pedraza et al.
SPRINGERPLUS (2015)
Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: What happens after one year?
Eva Cernuda-Morollon et al.
CEPHALALGIA (2015)
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study
Lars J. Stovner et al.
CEPHALALGIA (2014)
Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK
Modar Khalil et al.
JOURNAL OF HEADACHE AND PAIN (2014)
Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)
L. M. Bloudek et al.
JOURNAL OF HEADACHE AND PAIN (2012)
Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS)
A. M. Blumenfeld et al.
CEPHALALGIA (2011)
Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review
Michel Lanteri-Minet et al.
CEPHALALGIA (2011)
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56-Week PREEMPT Clinical Program
Sheena K. Aurora et al.
HEADACHE (2011)
Global prevalence of chronic migraine: A systematic review
J. L. Natoli et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
Method of Injection of OnabotulinumtoxinA for Chronic Migraine: A Safe, Well-Tolerated, and Effective Treatment Paradigm Based on the PREEMPT Clinical Program
Andrew Blumenfeld et al.
HEADACHE (2010)
Employment and Work Impact of Chronic Migraine and Episodic Migraine
Walter F. Stewart et al.
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE (2010)
Chronic migraine in the population - Burden, diagnosis, and satisfaction with treatment
Marcelo E. Bigal et al.
NEUROLOGY (2008)
Validation of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v. 2.1) for patients undergoing prophylactic migraine treatment
Jason C. Cole et al.
QUALITY OF LIFE RESEARCH (2007)
Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study
H-C Diener et al.
CEPHALALGIA (2007)
Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D
SJ Walters et al.
QUALITY OF LIFE RESEARCH (2005)
Validity and reliability of the Migraine-Specific Quality of Life Questionnaire (MSQ version 2.1)
BC Martin et al.
HEADACHE (2000)
分享论文
